ArticleScientific reports2025
Differential impacts of interstitial lung disease and airway disease on rheumatoid arthritis disease activity and infection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to distinguish the individual effects of interstitial lung disease (ILD) and airway disease (AD) on rheumatoid arthritis (RA) disease activity and infection. RA patients who underwent chest CT at Kanazawa University Hospital (2011-2021) were investigated. The primary outcome was infection-related hospitalization, and the secondary was RA disease activity (DAS28-CRP, SDAI) at final observation. Of 569 patients, 125 (22.0%) had ILD (ILD +), and 171 (30.1%) had AD (AD +). At first CT: RA disease activity was similar; ILD + received less methotrexate than ILD-; all DMARDs were similar in AD + and AD-. At final observation (mean: 73.9 months): RA disease activity was higher in ILD + and AD + . Analysis of covariance revealed a significant association between final RA disease activity and ILD, but not AD. Kaplan-Meier analysis showed lower infection-free rates in ILD + and AD + . Cox regression analysis with time-dependent covariates showed an association between infection and ILD after 50 months and AD (HR 3.702 and 1.744). RA disease activity was independently associated with ILD, likely due to reduced methotrexate use. ILD after 50 months and AD both increased infection risk independently. Distinguishing ILD from AD is important for selecting safe and effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.